长效,长效和超长效的抗肥胖
Eric L Schneider1, John A Hangasky1, Gary W Ashley1
1ProLynx, Inc., 135 Mississippi Street, San Francisco, California 94107, United States.
Journal of medicinal chemistry
|February 3, 2025
概括
研究人员正在开发延长释放性抗肥胖,以改善体重管理. 新型前药物策略的目标是每月甚至6个月的剂量间隔,提高患者的便利性和治疗效率.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物运输 药物运输 药物运输
- 代谢疾病 代谢疾病
背景情况:
- 肥胖是一种复杂的代谢疾病,需要有效的长期管理策略.
- 目前的抗肥胖类疗法往往需要频繁的服用,从而限制了患者的坚持.
- 开发具有延长作用时间的对于改善治疗结果至关重要.
研究的目的:
- 审查目前制造长效抗肥胖的技术.
- 探索开发超长效果前药物的新方法.
- 评估抗肥胖治疗药物剂量间隔显著延长的可能性.
主要方法:
- 审查现有的改技术:脂化,PEGylation和Fc融合.
- 描述使用预编程可释放链接器的宏分子原药.
- 关于利用清除率的新型原药修改的建议.
主要成果:
- 脂化,PEGylation和Fc融合使每周一次的施用成为可能,但较长的时间间隔受到限制.
- 大分子前药物显示出每周至每月剂量的前景.
- 新型前药物设计可以实现超长半衰期 (>1个月).
结论:
- 改性GLP-1激动剂的产药可以达到超长效的效果.
- 3至6个月的潜在剂量间隔可以通过先进的前药物策略来实现.
- 这些进展为改善抗肥胖治疗的坚持和有效性提供了显著的潜力.
相关概念视频
Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292
Insulin Formulations: Types and Delivery
162
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
162
Regulation of Food Intake
181
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
181
Oral Hypoglycemic Agents: Glinides
133
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
133
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K


